List of Excipients in Branded Drug LANOXIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Covis Pharmaceuticals Inc	LANOXIN	digoxin	24987-262	ALCOHOL
Covis Pharmaceuticals Inc	LANOXIN	digoxin	24987-262	ANHYDROUS CITRIC ACID
Covis Pharmaceuticals Inc	LANOXIN	digoxin	24987-262	PROPYLENE GLYCOL
Covis Pharmaceuticals Inc	LANOXIN	digoxin	24987-262	SODIUM PHOSPHATE, DIBASIC
Advanz Pharma (US) Corp	LANOXIN	digoxin	59212-242	D&C YELLOW NO. 10
Advanz Pharma (US) Corp	LANOXIN	digoxin	59212-242	FD&C YELLOW NO. 6

Lanoxin Excipient Strategy and Commercial Opportunities in Digoxin Products

Last updated: August 23, 2026

Lanoxin is an established digoxin product with no meaningful new-molecule exclusivity barrier in the United States. Its commercial opportunity is therefore concentrated in formulation execution: excipient safety, pediatric acceptability, injectable compatibility, supply reliability, and differentiated dosage forms. The strongest opportunities are alcohol-reduced or alcohol-free oral liquids, low-volume pediatric presentations, preservative and allergen control, and robust generic or specialty-pharmacy supply.

What is Lanoxin and which dosage forms use excipients?

Lanoxin contains digoxin, a cardiac glycoside used for selected patients with heart failure and for ventricular-rate control in chronic atrial fibrillation. The U.S. product line includes tablets, oral solution, and injection presentations. Digoxin has a narrow therapeutic index, so excipient changes can affect dissolution, absorption, tolerability, stability, and dose-measurement risk.

Lanoxin presentation	Typical U.S. strengths or concentration	Primary excipient strategy
Tablets	62.5 mcg, 125 mcg, 250 mcg	Solid-dose manufacturing, content uniformity, tablet disintegration, color and identification
Pediatric oral solution	0.05 mg/mL	Solubilization, sweetness, viscosity, preservative and alcohol management
Injection	0.25 mg/mL	Co-solvent system, pH control, sterility, container compatibility, precipitation control

The product label identifies formulation-specific inactive ingredients. The tablet formulation uses conventional solid-dose excipients, while the oral solution and injection use liquid vehicles and solubilizing systems appropriate to digoxin's low aqueous solubility. Exact excipient composition should be assessed by presentation and market because Lanoxin labeling can differ across jurisdictions and manufacturers. (U.S. Food and Drug Administration [FDA], 2024a; DailyMed, 2024a)

What excipients are used in Lanoxin tablets?

Lanoxin tablets use conventional excipients associated with compression, binding, lubrication, coating or surface finishing, and product identification. The commercial function of the tablet excipient system is more important than ingredient novelty because digoxin tablets are mature products with established generic competition.

Key formulation objectives include:

• Maintaining low-dose content uniformity at 62.5 mcg and 125 mcg strengths.
• Achieving consistent dissolution despite very low drug loading.
• Controlling tablet friability and breakage during packaging and distribution.
• Preserving strength-specific color coding without creating unnecessary colorant exposure.
• Minimizing variability caused by particle-size differences, segregation, and blend uniformity.
• Supporting automated manufacturing and high-throughput quality control.

Low-dose digoxin creates a content-uniformity challenge. A 62.5-mcg tablet contains a small quantity of active pharmaceutical ingredient relative to the total tablet mass. Direct compression may be commercially attractive, but wet granulation or ordered mixing can provide better control where the active has poor flow or segregation risk.

Which tablet excipient changes could create differentiation?

Potential differentiation includes:

1. A low-colorant or colorant-free tablet range for patients with excipient sensitivities.
2. A lower-lactose formulation for patients who avoid lactose, subject to acceptable stability and manufacturability.
3. A rapidly disintegrating or orally dispersible tablet for patients with dysphagia.
4. A scored tablet that supports dose flexibility, if dose uniformity after splitting is demonstrated.
5. A smaller tablet for geriatric patients using multiple medicines.
6. A packaging system that reduces moisture exposure and tablet mix-ups.

A new excipient combination alone may not create strong patent protection. Patent value would be higher if the formulation produced a measurable technical effect, such as improved content uniformity, enhanced stability, reduced tablet size, improved splitting accuracy, or a clinically relevant reduction in administration error.

What excipients are used in Lanoxin oral solution?

Lanoxin oral solution requires a vehicle capable of maintaining digoxin in solution over the labeled shelf life. The product label identifies excipients including liquid vehicles, sweetening agents, buffering components, and flavoring. The formulation also contains alcohol and propylene glycol in the U.S. product labeling. (FDA, 2024a)

These excipients create several commercial and regulatory issues:

• Alcohol exposure is relevant for children, pregnant patients, patients with alcohol-use concerns, and institutions with alcohol-restriction policies.
• Propylene glycol exposure can be important in neonates, infants, patients with renal impairment, and patients receiving multiple propylene-glycol-containing medicines.
• Sweeteners can affect tolerability, dental considerations, and suitability for specific metabolic conditions.
• Flavoring can improve adherence but can also narrow supplier options and create reformulation work.
• Viscosity affects dose-measurement accuracy and the performance of oral syringes.

A competing product with reduced alcohol and propylene glycol exposure could have commercial value if it maintains digoxin solubility, chemical stability, palatability, and dose accuracy. The product would need a complete pharmaceutical equivalence and bioequivalence strategy if submitted as an ANDA. A meaningful change in the solution vehicle can complicate comparative bioavailability and may require formulation-specific regulatory justification.

What is the strongest oral-liquid opportunity?

The most attractive opportunity is a ready-to-use pediatric digoxin solution with:

• Alcohol-free or substantially reduced-alcohol formulation.
• Reduced propylene glycol exposure.
• A stable, water-compatible solubilization system.
• Neutral or broadly acceptable flavor.
• Graduated oral syringe packaging.
• Child-resistant packaging with low administration force.
• A concentration that reduces dosing-volume error without creating overdose risk.

The commercial tradeoff is concentration. A higher concentration lowers administration volume but increases the consequence of a decimal or syringe error. A lower concentration may improve dosing safety but increase the volume burden for infants and small children. A successful product would need clear concentration labeling, a dedicated syringe, and human-factors testing.

What excipients are used in Lanoxin injection?

Lanoxin injection uses a sterile liquid system containing digoxin with co-solvents and pH-control components. The U.S. labeling identifies alcohol and propylene glycol among the inactive ingredients. (FDA, 2024b; DailyMed, 2024b)

The injectable product has a different risk profile from the oral products. Commercially relevant formulation attributes include:

• Absence of visible particles and precipitation.
• Sterility assurance.
• Compatibility with the primary container and closure.
• Stability during refrigerated and room-temperature storage.
• Compatibility with dilution fluids and administration equipment.
• Control of extractables and leachables.
• Management of alcohol and propylene glycol exposure.
• Reliable supply of sterile-grade excipients.

A generic or alternate injectable product must demonstrate more than chemical equivalence. Manufacturing controls, container-closure integrity, aseptic processing, stability, and in-use compatibility are central barriers. These requirements favor suppliers with established sterile manufacturing infrastructure.

Can an alcohol-free digoxin injection create a commercial niche?

Potentially, but the technical barrier is higher than for an oral solution. Digoxin's limited aqueous solubility means that replacing co-solvents may cause precipitation, adsorption, concentration drift, or reduced shelf life. A reformulation could be commercially valuable in neonatal, pediatric, critical-care, or alcohol-restricted settings, but it would require a strong stability and compatibility package.

The most defensible product concept would combine a new vehicle with a specific technical benefit, such as reduced excipient exposure while preserving injectable concentration and shelf life. A simple excipient substitution is less likely to produce durable differentiation.

When does Lanoxin lose exclusivity?

Lanoxin has no meaningful remaining new-molecule exclusivity in the United States. Digoxin is an old active ingredient, and multiple generic digoxin products are approved. The main U.S. commercial barrier is therefore not FDA exclusivity but regulatory approval, manufacturing quality, supply continuity, and clinical confidence in a narrow-therapeutic-index drug.

Exclusivity category	Lanoxin position
New chemical entity exclusivity	Expired or unavailable for this mature product
Orphan-drug exclusivity	Not the principal protection for Lanoxin
Pediatric exclusivity	No current commercial effect identified
Patent exclusivity	No material current protection expected to block ordinary generic digoxin development
Regulatory pathway	NDA for the branded product; ANDA pathway for qualifying generics
Main competitive barrier	Product quality, bioequivalence, supply, and physician or hospital acceptance

The FDA Orange Book should be checked for the current listing, patents, and exclusivity status at the time of filing or launch because Orange Book entries can change. The historic age of digoxin means a new entrant would generally compete through an ANDA, a 505(b)(2) application for a differentiated formulation, or a specialty product strategy. (FDA, 2024c)

What patents protect Lanoxin and its excipient formulations?

The original digoxin composition and conventional Lanoxin excipient systems are not expected to have commercially relevant live U.S. patent protection. Any historical patents covering the active ingredient, dosage forms, or manufacturing methods would generally have expired given the age of the product.

A new formulation could still support patent filings if it claims:

• A novel solubilizer or co-solvent system.
• A defined excipient ratio that improves stability.
• Reduced alcohol or propylene glycol exposure.
• A pediatric liquid with improved palatability and dose accuracy.
• A controlled-release or modified-release digoxin dosage form.
• A specific container-closure system that limits adsorption or degradation.
• A manufacturing process that improves low-dose content uniformity.
• A method that reduces administration errors through concentration, device, or labeling design.

Patent strength would depend on demonstrated performance. Broad claims to digoxin combined with ordinary pharmaceutical excipients would face substantial validity and obviousness risk. Narrow claims tied to comparative stability, dissolution, pharmacokinetics, or administration accuracy would be stronger if supported by reproducible data.

What formulation patents are commercially defensible?

The strongest potential claim sets would combine composition, process, and use claims:

Patent strategy	Potential technical effect	Relative strength
Alcohol-free oral solution	Reduced excipient exposure with maintained solubility and stability	Medium to high if data are strong
Low-volume pediatric solution	Reduced administration burden with dosing accuracy	Medium
Novel solubilizer system	Improved stability or reduced precipitation	Medium to high
Modified-release tablet	Reduced peak-trough fluctuation or dosing frequency	High technical burden
Tablet content-uniformity process	Better low-dose manufacturing control	Medium
Oral syringe and concentration system	Reduced dosing error	Medium, often vulnerable to design-around
New injection vehicle	Lower co-solvent exposure with equivalent stability	High technical burden

Are Lanoxin formulation patents listed in the Orange Book?

The Orange Book is the primary U.S. source for patents and exclusivity associated with approved drug products. A current review should focus on the Lanoxin NDA listing and any patents listed against the relevant dosage forms. For a mature digoxin product, the expected result is no blocking patent estate comparable to those protecting newer cardiovascular medicines. (FDA, 2024c)

A company launching a standard digoxin tablet or oral solution would face substantially less patent risk than a company developing a novel modified-release product or a 505(b)(2) formulation. The latter could create its own patent estate but could also trigger patent-certification and litigation issues if it references a listed drug with relevant patents.

Which companies are challenging Lanoxin with generics?

Generic competition already exists for digoxin tablets, oral solution, and injection presentations. The market includes established generic manufacturers and potential contract manufacturers operating under ANDA approvals. The practical competitive question is not whether generic entry is legally possible. It is whether an entrant can maintain supply, meet narrow-therapeutic-index quality expectations, and obtain sufficient commercial volume.

Potential competitors fall into four groups:

1. Conventional generic tablet manufacturers.
2. Generic liquid manufacturers with oral-solution capability.
3. Sterile injectable manufacturers.
4. Specialty pharmaceutical companies developing differentiated pediatric or excipient-reduced products.

Public FDA approval records identify approved products, but they do not always provide a complete commercial picture of active marketing, inventory, contract supply, or distributor participation. Commercial diligence should distinguish an approved ANDA from a product that is currently marketed at scale.

What Paragraph IV challenges affect Lanoxin?

A conventional Lanoxin generic launch is unlikely to depend on a new Paragraph IV challenge because the relevant product and active ingredient are old and generic digoxin products are already approved. Paragraph IV risk would become more relevant if a new applicant were addressing a later-listed formulation patent, a modified-release product, or a differentiated 505(b)(2) product with listed patents.

The main legal scenarios are:

• Paragraph III certification where a listed patent remains valid but the applicant accepts delayed launch.
• Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed.
• Section viii statement carving out a patented method of use.
• No-certification or no-relevant-patent pathway for an unprotected mature dosage form.

For standard digoxin products, manufacturing and regulatory execution are likely to dominate litigation exposure. For a novel liquid or injectable formulation, the applicant's own patents could become a commercial asset but also a target for validity challenges.

What method-of-use patents cover digoxin?

Digoxin's historical use in heart failure and atrial fibrillation is well established. Broad method-of-use claims for these indications are unlikely to provide current market exclusivity. New method claims could be pursued for a narrowly defined population, dosing algorithm, therapeutic-drug-monitoring strategy, or combination treatment, but patentability and clinical utility would require a specific technical disclosure.

Potential claim areas include:

• Genotype-guided digoxin dosing.
• Renal-function-based dosing algorithms.
• Pediatric dosing using a defined concentration and device.
• Therapeutic drug monitoring tied to a specific sampling interval.
• Use in a narrowly defined heart-failure phenotype.
• Combination treatment with a defined clinical endpoint.

Use patents may be difficult to enforce when physicians prescribe digoxin for multiple established indications. A label carve-out can also reduce the practical reach of method-of-use protection if the unpatented indications remain commercially meaningful.

What FDA regulatory pathway applies to a new Lanoxin product?

The regulatory pathway depends on the degree of formulation change.

Product concept	Likely pathway	Key regulatory burden
Same-strength tablet with same dosage form	ANDA	Pharmaceutical equivalence, bioequivalence, CMC, labeling
Same-strength oral solution with revised excipients	ANDA if requirements are met	Comparative formulation, bioequivalence, stability, excipient justification
Alcohol-free or lower-excipient oral liquid	ANDA or 505(b)(2), depending on differences	Bridging, clinical pharmacology, CMC, tolerability
Novel concentration or device combination	505(b)(2) may be appropriate	Dose-delivery, human factors, clinical or PK evidence
Modified-release digoxin	505(b)(2) or new application strategy	Release mechanism, PK, safety, clinical justification
New sterile injection vehicle	ANDA or 505(b)(2)	Sterility, container closure, compatibility, stability, bioequivalence

FDA guidance emphasizes that excipients in ANDA products must be appropriate for the dosage form, route, and proposed level of use. A novel excipient or materially higher exposure can increase the regulatory burden. (FDA, 2019)

How strong is the Lanoxin patent estate?

The patent estate is weak as a barrier to standard generic entry but could become meaningful around a technically differentiated formulation. Its current value is best characterized as follows:

Asset area	Estimated commercial defensibility
Original digoxin molecule	Very low
Conventional tablets	Very low
Conventional oral solution	Very low
Conventional injection	Low to medium because sterile manufacturing is difficult
Alcohol-reduced pediatric liquid	Medium if protected by robust data
Modified-release product	Medium to high, but development risk is substantial
Administration-device system	Medium, with design-around risk
Manufacturing process	Medium if process-specific and difficult to replicate

Patent strength should not be confused with market attractiveness. A weak patent position can still support a profitable product if competitors have exited, supply is unreliable, or the product serves hospitals and pediatric specialists with limited alternatives.

What commercial opportunities exist for Lanoxin excipients?

Pediatric and geriatric liquid products

The most direct opportunity is a palatable, excipient-reduced oral solution paired with an oral syringe. Pediatric heart-failure and arrhythmia use requires accurate low-volume dosing, while geriatric patients may have swallowing and adherence challenges.

Hospital injectable supply

A reliable digoxin injection supplier can compete on fill-finish quality, shortage prevention, and hospital contracting. The market is more operationally demanding than the tablet market, but supply interruptions can create purchasing opportunities.

Excipient-reduced products

Alcohol-free, lower-propylene-glycol, low-sugar, or low-colorant formulations could target hospitals, pediatric prescribers, and patients with excipient restrictions. The commercial claim must be supported by measurable safety, tolerability, stability, or adherence benefits.

Contract development and manufacturing

Excipient suppliers can pursue value through formulation development rather than commodity sales. Relevant services include:

• Solubility screening.
• Liquid stability optimization.
• Low-dose blend uniformity.
• Sterile injectable compatibility.
• Extractables and leachables assessment.
• Oral-syringe dose-delivery validation.
• Global excipient regulatory documentation.

What generic launch risks exist for Lanoxin?

Generic entry risk is high for standard presentations because the active ingredient is old and generic products are established. The main launch risks are commercial and technical:

• Narrow-therapeutic-index expectations.
• Batch-to-batch content-uniformity failures.
• Dissolution variability.
• Liquid precipitation or concentration drift.
• Excipient toxicity in vulnerable populations.
• Injectable supply-chain failures.
• Hospital substitution and formulary barriers.
• Low market size relative to development and validation costs.
• Difficulty securing qualified excipient suppliers.
• Product liability exposure from dosing errors.

A differentiated entrant can reduce price competition by targeting an unmet formulation need, but it will face higher development and regulatory costs.

How does Lanoxin compare with competing digoxin products?

Factor	Lanoxin brand	Standard generic digoxin	Differentiated formulation opportunity
Active ingredient	Digoxin	Digoxin	Digoxin
Patent barrier	Minimal current barrier	Minimal current barrier	Potentially meaningful if novel
Price position	Historically branded	Usually lower	Premium possible for documented benefit
Excipient differentiation	Limited	Usually limited	Main commercial lever
Pediatric positioning	Established oral-liquid use	Varies by supplier	Strong opportunity with device and excipient redesign
Injectable risk	Sterile manufacturing and supply	Same technical burden	Potential niche if vehicle or supply improves
Regulatory pathway	NDA	ANDA	ANDA or 505(b)(2)
Main competitive advantage	Brand recognition and availability	Price and supply	Safety, usability, stability, or shortage resilience

Key Takeaways

• Lanoxin's commercial opportunity is driven by formulation and supply performance, not active-ingredient exclusivity.
• Standard digoxin tablets face high generic competition and limited patent protection.
• Oral solution reformulation offers the clearest excipient opportunity.
• Alcohol and propylene glycol reduction could differentiate a pediatric or institutional product if solubility and stability are preserved.
• Injectable development has higher technical barriers because of sterility, precipitation, container compatibility, and co-solvent requirements.
• Conventional excipient patents would be weak unless tied to a demonstrated technical effect.
• A new product would likely use the ANDA pathway for a substantially equivalent dosage form and 505(b)(2) for material formulation or delivery changes.
• Device integration, dose accuracy, low excipient exposure, and supply reliability offer stronger commercial positioning than a simple tablet reformulation.
• No current Lanoxin patent estate is expected to block ordinary generic digoxin entry, subject to confirmation in the current FDA Orange Book.

FAQs

Can a company market an alcohol-free Lanoxin oral solution?

Yes, but the product must demonstrate adequate digoxin solubility, stability, bioequivalence, palatability, and dosing performance. The regulatory pathway could be an ANDA or 505(b)(2), depending on the formulation differences.

Is lactose removal from Lanoxin tablets a strong patent opportunity?

Lactose removal alone is unlikely to support a strong patent position. Patent value would improve if the replacement excipient system produced superior content uniformity, stability, dissolution, or tablet performance.

Would a digoxin orally disintegrating tablet qualify for generic approval?

A materially different dosage form may require a 505(b)(2) pathway rather than a conventional ANDA. The applicant would need to address dose uniformity, disintegration, absorption, labeling, and patient administration.

Why is digoxin injectable manufacturing more difficult than tablet manufacturing?

The injection requires sterile processing, container-closure integrity, control of co-solvent systems, prevention of precipitation, and compatibility with dilution and administration conditions.

Can a dedicated oral syringe create patent protection for a digoxin liquid?

A syringe and concentration system can support device or combination-product claims, particularly if it reduces dosing errors. Its patent strength depends on technical novelty and clinical or human-factors evidence, and competitors may design around narrow claims.

References

1. DailyMed. (2024a). Lanoxin: Digoxin tablet and oral solution prescribing information. U.S. National Library of Medicine.
2. DailyMed. (2024b). Lanoxin: Digoxin injection prescribing information. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2019). ANDAs for certain highly purified synthetic peptides. FDA.
4. U.S. Food and Drug Administration. (2024a). Lanoxin digoxin tablets and oral solution: U.S. prescribing information. FDA.
5. U.S. Food and Drug Administration. (2024b). Lanoxin digoxin injection: U.S. prescribing information. FDA.
6. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.